Thunberg, C AMorozowich, S TRamakrishna, Harish2015-08-222015-08-222015-07Thunberg C A, Morozowich S T, Ramakrishna Harish. Inhaled therapy for the management of perioperative pulmonary hypertension. Annals of Cardiac Anaesthesia. 2015 Jul; 18(3): 394-402.http://imsear.searo.who.int/handle/123456789/162345Patients with pulmonary hypertension (PH) are at high risk for complications in the perioperative setting and often receive vasodilators to control elevated pulmonary artery pressure (PAP). Administration of vasodilators via inhalation is an effective strategy for reducing PAP while avoiding systemic side effects, chiefly hypotension. The prototypical inhaled pulmonary‑specific vasodilator, nitric oxide (NO), has a proven track record but is expensive and cumbersome to implement. Alternatives to NO, including prostanoids (such as epoprostenol, iloprost, and treprostinil), NO‑donating drugs (sodium nitroprusside, nitroglycerin, and nitrite), and phosphodiesterase inhibitors (milrinone, sildenafil) may be given via inhalation for the purpose of treating elevated PAP. This review will focus on the perioperative therapy of PH using inhaled vasodilators.enNitric oxide‑donating drugsPhosphodiesterase inhibitorsProstanoidsPrototypical inhaledpulmonary‑specific vasodilatorAdministration, InhalationAnesthetics, InhalationHumansHypertension, Pulmonary --drug therapyHypertension, Pulmonary --epidemiologyNitric Oxide Donors --administration & dosagePerioperative PeriodPhosphodiesterase InhibitorsVasodilator Agents --administration & dosageArticle